CN1192360A - Medicinal prepn. contg. beneficial bacteria named 'Junyikang' and method for preparing same - Google Patents
Medicinal prepn. contg. beneficial bacteria named 'Junyikang' and method for preparing same Download PDFInfo
- Publication number
- CN1192360A CN1192360A CN97115093A CN97115093A CN1192360A CN 1192360 A CN1192360 A CN 1192360A CN 97115093 A CN97115093 A CN 97115093A CN 97115093 A CN97115093 A CN 97115093A CN 1192360 A CN1192360 A CN 1192360A
- Authority
- CN
- China
- Prior art keywords
- junyikang
- preparation
- bifidus
- viable count
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000894006 Bacteria Species 0.000 title claims abstract description 45
- 230000009286 beneficial effect Effects 0.000 title claims abstract description 30
- 238000000034 method Methods 0.000 title claims description 15
- 241000186016 Bifidobacterium bifidum Species 0.000 claims abstract description 46
- 238000000855 fermentation Methods 0.000 claims abstract description 41
- 230000004151 fermentation Effects 0.000 claims abstract description 41
- 241000186000 Bifidobacterium Species 0.000 claims abstract description 14
- 240000001046 Lactobacillus acidophilus Species 0.000 claims abstract description 8
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims abstract description 7
- 241000186012 Bifidobacterium breve Species 0.000 claims abstract description 5
- 241001608472 Bifidobacterium longum Species 0.000 claims abstract description 5
- 229940009291 bifidobacterium longum Drugs 0.000 claims abstract description 4
- 229940002008 bifidobacterium bifidum Drugs 0.000 claims abstract description 3
- 238000002360 preparation method Methods 0.000 claims description 57
- 230000000968 intestinal effect Effects 0.000 claims description 36
- 239000000284 extract Substances 0.000 claims description 24
- 239000002609 medium Substances 0.000 claims description 23
- 239000007788 liquid Substances 0.000 claims description 21
- 238000002156 mixing Methods 0.000 claims description 19
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 16
- 239000008103 glucose Substances 0.000 claims description 16
- 229940041514 candida albicans extract Drugs 0.000 claims description 14
- 239000008267 milk Substances 0.000 claims description 14
- 235000013336 milk Nutrition 0.000 claims description 14
- 210000004080 milk Anatomy 0.000 claims description 14
- 239000000843 powder Substances 0.000 claims description 14
- 239000012137 tryptone Substances 0.000 claims description 14
- 239000012138 yeast extract Substances 0.000 claims description 14
- 235000015278 beef Nutrition 0.000 claims description 13
- 229920001542 oligosaccharide Polymers 0.000 claims description 12
- 150000002482 oligosaccharides Chemical class 0.000 claims description 12
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 claims description 10
- 239000000047 product Substances 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 239000012153 distilled water Substances 0.000 claims description 8
- -1 electuary Substances 0.000 claims description 8
- 239000001963 growth medium Substances 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 6
- 244000068988 Glycine max Species 0.000 claims description 5
- 235000010469 Glycine max Nutrition 0.000 claims description 5
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 5
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 5
- 229930182830 galactose Natural products 0.000 claims description 5
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 claims description 5
- 229960000511 lactulose Drugs 0.000 claims description 5
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 claims description 5
- 241000207199 Citrus Species 0.000 claims description 4
- 241000193171 Clostridium butyricum Species 0.000 claims description 4
- 241000196324 Embryophyta Species 0.000 claims description 4
- 235000020971 citrus fruits Nutrition 0.000 claims description 4
- 230000036541 health Effects 0.000 claims description 4
- 238000011081 inoculation Methods 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- AYRXSINWFIIFAE-SCLMCMATSA-N Isomaltose Natural products OC[C@H]1O[C@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@@H](O)[C@@H](O)[C@@H]1O AYRXSINWFIIFAE-SCLMCMATSA-N 0.000 claims description 3
- 241000194020 Streptococcus thermophilus Species 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 238000005516 engineering process Methods 0.000 claims description 3
- 235000020710 ginseng extract Nutrition 0.000 claims description 3
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 claims description 3
- 239000011573 trace mineral Substances 0.000 claims description 3
- 235000013619 trace mineral Nutrition 0.000 claims description 3
- 239000011782 vitamin Substances 0.000 claims description 3
- 229940088594 vitamin Drugs 0.000 claims description 3
- 229930003231 vitamin Natural products 0.000 claims description 3
- 235000013343 vitamin Nutrition 0.000 claims description 3
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 3
- PVXPPJIGRGXGCY-TZLCEDOOSA-N 6-O-alpha-D-glucopyranosyl-D-fructofuranose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)C(O)(CO)O1 PVXPPJIGRGXGCY-TZLCEDOOSA-N 0.000 claims description 2
- 229920001661 Chitosan Polymers 0.000 claims description 2
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 claims description 2
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 claims description 2
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 235000013305 food Nutrition 0.000 claims description 2
- 235000013373 food additive Nutrition 0.000 claims description 2
- 239000002778 food additive Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000003094 microcapsule Substances 0.000 claims description 2
- 150000002772 monosaccharides Chemical class 0.000 claims description 2
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 claims description 2
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 claims description 2
- 206010010774 Constipation Diseases 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 7
- 208000001848 dysentery Diseases 0.000 abstract description 6
- 230000008901 benefit Effects 0.000 abstract description 3
- 210000000936 intestine Anatomy 0.000 abstract 3
- 241000193403 Clostridium Species 0.000 abstract 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 abstract 1
- 244000005700 microbiome Species 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 235000018291 probiotics Nutrition 0.000 description 6
- 238000005303 weighing Methods 0.000 description 6
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 244000052616 bacterial pathogen Species 0.000 description 4
- 239000012467 final product Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000006041 probiotic Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- 238000009395 breeding Methods 0.000 description 3
- 230000001488 breeding effect Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000008518 lycium barbarum polysaccharide Substances 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 3
- 229960001180 norfloxacin Drugs 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000007160 gastrointestinal dysfunction Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 1
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 description 1
- 241001672694 Citrus reticulata Species 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 235000002710 Ilex cornuta Nutrition 0.000 description 1
- 241001310146 Ilex cornuta Species 0.000 description 1
- 108010070716 Intercellular Signaling Peptides and Proteins Proteins 0.000 description 1
- 102000005755 Intercellular Signaling Peptides and Proteins Human genes 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 235000010326 Osmanthus heterophyllus Nutrition 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000009264 composting Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 229940032049 enterococcus faecalis Drugs 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000002650 habitual effect Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Junyikang prepn. is made by mixed fermentation or separate fermentation of one or more kinds of bifidobacteria and one or more kinds of intestine beneficial bacterium and combination with one or more kinds of bifido factor. The bifidobacteria used include bifidobacterium infontis, bifidobacterium longum, bifidobacterium breve and bifidobacterium bifidum. The intestine beneficial bacteria used include clostridium butyrium, lactobacillus acidophilus and stretococcus thermophilus. This prepn. possesses the advantages of quick improvement the ecological balance in intestine and obvious curing effect to dysentery and constipation.
Description
The present invention relates to a kind of microorganism formulation.
Healthy people's intestinal microbial population mainly is made up of anaerobe such as bacillus bifidus, lactobacillus, enterococcus faecalis and a spot of escherichia coli etc.Under the normal condition, the ratio of anaerobe and aerobic organism is about 400: 1, and anaerobe such as bacillus bifidus have comparative advantage.These probioticss are combined closely with intestinal epithelial cell and are constituted biological barrier on the intestinal surface, suppress the field planting growth of pathogenic bacterium, and produce lactic acid, acetic acid, and the outer glycosides enzyme of born of the same parents plays and reduces the intestinal pH value, decompose the effect of complicated polysaccharide, degraded toxin.On the contrary, if because the factor of environment, diet, medicine or microorganism causes the intestinal microbial population balance destroyed, and pathogenic bacterium breed in a large number, probiotics quantity reduces, and then will cause the function of intestinal canal disorder, and diseases such as enteritis, diarrhoea, vomiting take place.At this moment, if take antibiotics, although can control the breeding of pathogenic bacterium, probiotics has also been killed simultaneously, tended to that this thing happens, dysentery has been cured, and serious constipation has taken place again, and symptom is difficult to alleviate for a long time.In order to replenish intestinal beneficial bacterium, the scientific research people grinds and has done a large amount of work in this respect.In recent years, developed rapidly, and developed some products, and declared the patent of some this respects, but these products and patent all there are weak point at present based on the enteric microorganism preparation of bacillus bifidus, the one, mostly be single bifidobacterium preparations; The 2nd, the connection bacteria preparation is arranged, but do not contain bifidus factor; The 3rd, singly use bifidus factor.At present, single bifidobacterium preparations on the market or connection bacteria preparation product, though can play the effect that replenishes intestinal beneficial bacterium, owing to do not contain bifidus factor, growth rate is too slow.Although single bifidus factor preparation can promote the propagation of probiotics in the intestinal, Clinical Laboratory is the result show, check does not go out useful anaerobe such as bacillus bifidus in crowd's intestinal of quite a few non-health status.Particularly, the gerontal patient is even more serious, to such patient, also has few effect even take the bifidus factor preparation.
The purpose of this invention is to provide a kind of Junyikang preparation and technology thereof, this Junyikang preparation had both contained intestinal beneficial bacteriums such as bacillus bifidus, contain the bifidus factor that promotes bifidobacterium growth propagation again, this product has the advantage that suitable crowd improves intestinal eubiosis extensively, rapidly.This product is obvious to the therapeutic effect of dysentery, and dysentery patient then can control the breeding of pathogenic bacterium if taking this Junyikang preparation treats, and has replenished, promoted growth, the propagation of probiotics simultaneously, and intestinal microbial population ecology is restored balance rapidly, and the patient gets well.
For achieving the above object, the present invention takes following technical scheme: this Junyikang preparation is behind the bifidobacterium fermentation with one or more, cooperates one or more bifidus factor, made preparation.If more than one bacillus bifidus can ferment respectively or mixed culture fermentation.
Described bacillus bifidus includes bifidobacteria infantis, bifidobacterium longum, bifidobacterium breve, bifidobacterium bifidum, and its use level is: 1,000 ten thousand-400,000,000/one time doses of viable count.
Described bifidus factor is meant the growth to bacillus bifidus, the oligosaccharide substance that propagation has obvious facilitation, generally passes through the glycosidic bond be combined into by 2-10 monosaccharide; Or the material of extracted form natural plant; Or polysaccharose substance, described oligosaccharide substance comprises one or more in soybean oligo saccharide, oligofructose, oligomeric xylose, oligomeric galactose, oligomeric lactulose, oligomeric isomaltose, oligomeric isomaltulose, oligomeric glucose, Raffinose, stachyose, the chitosan, and its use level is dose of 0.5g-30g/.The material of described extracted form natural plant comprises one or more in Citrus pericarp extract, Radix Ginseng extract, Folium Camelliae sinensis extract, Fructus Lycii extract, the Fructus Schisandrae Chinensis extrat, and its use level is dose of 0.5g-30g/.Radix Ginseng extract wherein, Folium Camelliae sinensis extract, Fructus Lycii extract market is on sale, and Fructus Schisandrae Chinensis extrat, Citrus pericarp extract take known method to produce, and takes that water is carried, concentrated, drying makes.
Among the present invention, this Junyikang preparation also adopts one or more other intestinal beneficial bacterium fermentation back formulated, and described one or more bacillus bifidus and described one or more other intestinal beneficial bacterium can ferment respectively, also can mixed culture fermentation.
Described intestinal beneficial bacterium includes clostridium butyricum, bacillus acidophilus and streptococcus thermophilus, and its use level is 1,000 ten thousand-400,000,000/one time doses of viable count.
Junyikang preparation of the present invention can be used as food, health product, medicine or food additive.
Described Junyikang preparation can be made into capsule, microcapsule, electuary, granule, tablet, oral liquid.Manufacturing the various forms of products of above-mentioned Junyikang preparation, all is to adopt known commonsense method to make.
In described Junyikang preparation, also be combined with various vitamin and trace element.Above-mentioned various vitamin and trace element can suitably add according to the requirement of human body.
Manufacture the bacillus bifidus that contains one or more, and one or more the method for Junyikang of bifidus factor.This Junyikang preparation is made through following method:
(1) prepares fermentation medium with distilled water, this fermentation medium contains one or more in tryptone, yeast extract, the beef extract, and oligofructose, glucose, the consisting of of this fermentation medium (its content is percetage by weight): tryptone 0.5%-4%, yeast extract 0.5%-4%, beef extract 0.5%-4%, oligofructose 0.5%-4%, glucose 0.5%-4%
(2) with culture medium under 121 ℃ of conditions, sterilized 30 minutes, when being cooled to 37 ℃, inoculate one or more bacillus bifidus, under 37 ℃ of conditions, cultivated 18 hours, the control bacteria containing amount reaches 2.2 * 10
9It is individual/as during ml, to reclaim with continuous centrifuge and to obtain wet thallus,
(3) above-mentioned wet thallus is suspended from PH is 5.6, concentration is in 20% the defatted milk powder liquid, abundant mixing, freeze-dried mycopowder, it is 4.0 * 10 that control contains viable count
10It is individual/g,
(4) above-mentioned lyophilizing mycopowder and one or more bifidus factors are by following use level mixed preparing, its use level is: the viable count of one or more bacillus bifidus is 1,000 ten thousand-400,000,000/one time doses, one or more bifidus factor is dose of 0.5g-30g/, makes the Junyikang preparation at last.
Manufacture the bacillus bifidus that contains one or more, one or more Bacterium entericum, and one or more the Junyikang method of bifidus factor, this method is taked bacillus bifidus and Bacterium entericum composting fermentation.This Junyikang preparation is made through following method:
(1) prepares fermentation medium with distilled water, this fermentation medium contains one or more in tryptone, yeast extract, the beef extract, and oligofructose, glucose, the consisting of of this fermentation medium (its content is percetage by weight): tryptone 0.5%-4%, yeast extract 0.5%-4%, beef extract 0.5%-4%, oligofructose 0.5%-4%, glucose 0.5%-4%
(2) with culture medium under 121 ℃ of conditions, sterilized 30 minutes, when being cooled to 37 ℃, inoculate one or more bacillus bifidus, with one or more intestinal beneficial bacterium, under 37 ℃ of conditions, to cultivate 18 hours, the control bacteria containing amount: the bacillus bifidus intestinal beneficial bacterium is respectively 2.2 * 10
9It is individual/as during ml, to reclaim with continuous centrifuge and to obtain wet thallus,
(3) above-mentioned wet thallus is suspended from PH is 5.6, concentration is in 20% the defatted milk powder liquid, abundant mixing, freeze-dried mycopowder, it is 4.0 * 10 that control contains viable count
10It is individual/g,
(4) above-mentioned lyophilizing mycopowder and one or more bifidus factors are by following use level mixed preparing, its use level is: the viable count of one or more bacillus bifidus is 1,000 ten thousand-400,000,000/one time doses, one or more intestinal beneficial bacterium is 1,000 ten thousand-400,000,000/doses, one or more bifidus factor is dose of 0.5g-30g/, makes the Junyikang preparation at last.
Manufacture the bacillus bifidus that contains one or more, one or more Bacterium entericum, and one or more the Junyikang method of bifidus factor, this method is taked bacillus bifidus and Bacterium entericum fermentation method respectively.This Junyikang preparation is made through following method:
(1) prepares fermentation medium with distilled water, this fermentation medium contains one or more in tryptone, yeast extract, the beef extract, and oligofructose, glucose, the consisting of of this fermentation medium (its content is percetage by weight): tryptone 0.5%-4%, yeast extract 0.5%-4%, beef extract 0.5%-4%, oligofructose 0.5%-4%, glucose 0.5%-4%
(2) with culture medium under 121 ℃ of conditions, sterilized 30 minutes, when being cooled to 37 ℃, inoculate one or more bacillus bifidus, under 37 ℃ of conditions, cultivated 18 hours, the control bacteria containing amount reaches 2.2 * 10
9It is individual/as during ml, to reclaim with continuous centrifuge and to obtain wet thallus,
(3) above-mentioned wet thallus is suspended from PH is 5.6, concentration is in 20% the defatted milk powder liquid, abundant mixing, freeze-dried mycopowder, it is 4.0 * 10 that control contains viable count
10It is individual/g,
(4) with one or more intestinal beneficial bacterium seed liquor inoculation PH be 4.5, concentration is in 10% the defatted milk powder liquid, to cultivate 14 hours under 37 ℃ of conditions, obtains the intestinal beneficial bacterium fermentation liquid, it is 2.2 * 10 that control contains viable count
9Individual/ml.
(5) wet thallus of intestinal beneficial bacterium fermentation liquid and bacillus bifidus is suspended from PH is 5.6, concentration is in 20% the defatted milk powder liquid, abundant mixing, freeze-dried lyophilizing mycopowder, it is 4.5 * 10 that control contains viable count
10It is individual/g,
(6) above-mentioned lyophilizing mycopowder and one or more bifidus factors are by following use level mixed preparing, its use level is that the viable count of bacillus bifidus and intestinal beneficial bacterium is respectively 1,000 ten thousand-400,000,000/one time doses, bifidus factor is dose of 0.5g-30g/, makes the Junyikang preparation at last.
Maximum characteristics of the present invention and original creation part are, product according to the present invention produces had both contained intestinal beneficial bacteriums such as bacillus bifidus, contained the bifidus factor that promotes bifidobacterium growth propagation again, compare with product in the past, have the effect that suitable crowd improves intestinal eubiosis extensively, rapidly.The zoopery result who makes of mice shows that Junyikang preparation of the present invention is equivalent to norfloxacin to the therapeutic effect of dysentery, and does not have the side effect of norfloxacin.Norfloxacin because a large amount of probioticss are also killed, causes the intestinal microecology balance to be destroyed, and causes constipation when curing dysentery.To a little less than the 6 routine gastrointestinal functions and responsive, go on business and easily suffer from the patient of gastrointestinal dysfunction that being not acclimatized causes in the other places, begin to take Junyikang preparation of the present invention at the proxima luce (prox. luc) of going on business, still continued to take 2-3 days after having arrived the other places, being not acclimatized disease disappears as a result, illustrates that gastrointestinal dysfunction, diarrheal disease that being not acclimatized is caused are effective in cure.To the gerontal patient of 3 routine habitual constipations, took Junyikang preparation of the present invention 2 days, the constipation transference cure.The constipation transference cure is the result of the loosening bowel to relieve constipation dual function of replenishing, breeding in a large number of bacillus bifidus and oligosaccharide.
Bifidus factor sees Table 1 to the facilitation of bifidobacterium growth, propagation.The result shows that different oligosaccharide and plant extract to the facilitation of bifidobacterium growth, have certain difference.Two kinds are used and are better than single usefulness.In the table 1, the composition of ordinary culture medium is to contain peptone 1%, Carnis Bovis seu Bubali cream 0.5%, and NaCl 0.5% adds 0.5% bifidus factor on this basis, and above-mentioned each content is percetage by weight, observes the effect that promotes growth, reproduction.Bifidus factors such as table 1 oligosaccharide are to the influence of bifidobacterium growth
| The bifidus factor kind | Addition | Promote upgrowth situation |
| Control medium (not containing bifidus factor) | 0 | + |
| Oligofructose | 0.5％ | ++++ |
| Oligomeric galactose | 0.5％ | +++ |
| Oligomeric xylose | 0.5％ | ++++ |
| Oligomeric lactulose | 0.5％ | +++ |
| Oligomeric isomaltose | 0.5％ | ++ |
| Soybean oligo saccharide | 0.5％ | +++ |
| Lycium barbarum polysaccharide | 0.5％ | ++ |
| Citrus chachiensis Hort. Chinese holly peel extract | 0.5％ | ++++ |
| Oligofructose+lycium barbarum polysaccharide | 0.25％ 0.25％ | ++++ |
| Oligomeric galactose+soybean oligo saccharide | 0.25％ 0.25％ | ++++ |
Promote upgrowth situation: visual turbidity relatively
+ growth is general; ++ well-grown; +++-++ ++ growth is significantly.
Embodiment 1 (two kinds of bacillus bifidus mixed culture fermentation)
Add 100L distilled water preparation fermentation medium.
(its content is percetage by weight) composed as follows of fermentation medium: tryptone 1%, yeast extract 0.5%, beef extract 0.5%, glucose 1%, oligofructose 1%, sodium acetate 0.5%, calcium carbonate 0.05%.Under 121 ℃ of conditions, to sterilize 30 minutes, when being cooled to 37 ℃, inoculation baby and each lL of bifidobacterium breve seed liquor under 37 ℃ of conditions, cultivated 18 hours, and bacteria containing amount reaches 2.2 * 10
9Individual/as during ml, to use continuous centrifuge, with 15000r/ minute, centrifugal recovery obtained wet thallus 0.6kg, with above-mentioned wet thallus be suspended from that 14L, PH are 5.6, concentration is in 20% the defatted milk powder liquid, abundant mixing, freeze-dried mycopowder 3kg, containing viable count is 4.0 * 10
10Individual/g.This mycopowder can be used for the Junyikang preparation that different formulations is formed.The prescription composition is exemplified below:
1, lyophilizing mycopowder 2.5g.
Oligomeric galactose 2000g
Accurately take by weighing above-mentioned two kinds of components, with the abundant mixing of mixing machine, be sub-packed in 1000 bags, every bag contains bifidus factor 2g, and viable count is no less than 200,000,000.Can once take for every bag.
2, lyophilizing mycopowder 2.5g.
Oligomeric lactulose 2000g
V
c???10g
V
Bl??1500mg
V
B6??1500mg
V
Bl2?1500mg
Z
n???1300mg
Fe????12g
Accurately take by weighing above-mentioned 8 kinds of components,, be sub-packed in 1000 bags, get final product with the abundant mixing of mixing machine.Wherein every bag contains viable count and is no less than 200,000,000.Can once take for every bag.
Embodiment 2 (butyric acid bacteria and bacillus bifidus mixed culture fermentation)
Add 100L distilled water preparation fermentation medium.
(its content is percetage by weight) composed as follows of fermentation medium: tryptone 1%, yeast extract 1%, meat peptone 0.5%, glucose 1%, oligofructose l%, sodium acetate 0.5%, calcium carbonate 0.05%.Under 121 ℃ of conditions, sterilized 30 minutes, when being cooled to 37 ℃, inoculation clostridium butyricum and each 1L of bifidobacterium longum seed liquor, under 37 ℃ of conditions, cultivated 18 hours, with 15000r/ minute, centrifugal recovery obtained wet thallus 0.6kg with continuous centrifuge, the PH that is suspended from 14L is 5.6, concentration is in 20% the defatted milk powder liquid, abundant mixing, the freeze-dried mycopowder 3kg that gets, containing viable count is 4.0 * 10
10Individual/g.This mycopowder can be used for the Junyikang preparation that different formulations is formed, and the prescription composition is exemplified below:
1, lyophilizing mycopowder 5g
Oligomeric xylose 1200g
V
c?????????10g
V
B1????????1500mg
V
B6????????1500mg
Z
n?????????1300mg
Fe??????????12g
Accurately take by weighing above-mentioned 7 kinds of components, fully mixing is sub-packed in 1000 bags, gets final product.Every bag contains viable count and is no less than 200,000,000.Can once take for every bag.
2, lyophilizing mycopowder 5g
Citrus pericarp extract 500g
Oligomeric lactulose 1000g
V
c???????????10g
V
B1??????????1500mg
V
B2??????????1500mg
Accurately take by weighing above-mentioned six kinds of components, fully mixing is sub-packed in 1000 bags and gets final product.
Every bag contains viable count and is no less than 200,000,000.Can once take for every bag.
Embodiment 3 (bacillus bifidus and bacillus acidophilus are fermented respectively, and be freeze-dried mixed)
The condition of culture of the culture medium of bacillus bifidus and recovering condition are with embodiment 1.
Bacillus acidophilus's fermentation condition be with the PH that bacillus acidophilus's seed liquor 0.2L is inoculated in 10L be 4.5, concentration is in 10% the defatted milk powder liquid, under 37 ℃ of conditions, cultivated 14 hours, recovery thalline (0.6Kg) with whole fermentation liquids and bacillus bifidus, the PH that is suspended from 10L is 6.0, concentration is in 30% the defatted milk powder liquid, abundant mixing, lyophilizing gets mycopowder 3kg, and bacteria containing amount is 4.5 * 10
10Individual/g, this lyophilizing mycopowder not only contains bacillus bifidus but also contain the bacillus acidophilus, is used to prepare the beneficial bacterium health preparation of different formulations, is exemplified below:
1, lyophilizing mycopowder 5g
Oligomeric xylose 1000g
Lycium barbarum polysaccharide 500g
V
c?????????10g
V
B1????????1500mg
V
B6????????1500mg
Accurately take by weighing above-mentioned six kinds of components, fully mixing is sub-packed in 1000 bags.Wherein every bag contains viable count and is no less than 200,000,000, can once take for every bag.
2, lyophilizing mycopowder 5g
Oligofructose 1000g
Soybean oligo saccharide 1000g
V
c?????????10g
V
B1????????1500mg
V
B6????????1500mg
Z
n?????????1300mg
Fe??????????12g
Accurately take by weighing above-mentioned 8 kinds of components, fully mixing is sub-packed in 1000 bags, gets final product.Every bag contains viable count and is no less than 200,000,000.Can once take for every bag.
The bacillus bifidus in the beneficial bacterium health preparation of the present invention and the use level of intestinal beneficial bacterium are carried out proportioning by the contained viable count of dose, and the use level of bifidus factor is to carry out proportioning by the weight of a dose institute a unit of measure used in ancient China, and the Junyikang preparation of any weight of use level proportioning that all the present invention of pressing propose is all in claim scope of the present invention.
Microorganism fungus kind used in the present invention has been put into China Committee for Culture Collection of Microorganisms common micro-organisms center (Beijing, Zhong Guan-cun, postcode 100080) preservation, totally seven following microorganism fungus kinds on July 28th, 97.
(1) classification name: Clostridium butyricum clostridium butyricum, preserve numbering 0313-1.
(2) classification name: Bifidobacterium infantis bifidobacteria infantis, preserve numbering 0313-2., (3) classification name: Streptococcus thermophilus streptococcus thermophilus, preserve numbering 0313-3.
(4) classification name: Lactobacillus acidophilus bacillus acidophilus, preserve numbering 0313-4.
(5) classification name: Bifidobacterium longum bifidobacterium longum, preserve numbering 0313-5.
(6) classification name: Bifidobacterium breve bifidobacterium breve, preserve numbering 0313-6.
(7) classification name: Bifidobacterium bifidum bifidobacterium bifidum, preserve numbering 0313-7.
Above-mentioned seven microorganism fungus kinds detect through this microorganism center, and testing result is survival.
Claims (11)
1, a kind of Junyikang preparation is characterized in that: this Junyikang preparation is behind the bifidobacterium fermentation with one or more, cooperates one or more bifidus factor, made preparation.
2, Junyikang preparation according to claim 1, it is characterized in that: described bacillus bifidus includes bifidobacteria infantis, bifidobacterium longum, bifidobacterium breve, bifidobacterium bifidum, and its use level is 1,000 ten thousand-400,000,000/one time doses of viable count.
3, Junyikang preparation according to claim 2 is characterized in that: described bifidus factor is meant the growth to bacillus bifidus, the oligosaccharide substance that propagation has obvious facilitation, generally passes through the glycosidic bond be combined into by 2-10 monosaccharide; Or the material of extracted form natural plant; Or polysaccharose substance, described oligosaccharide substance comprises one or more in soybean oligo saccharide, oligofructose, oligomeric xylose, oligomeric galactose, oligomeric lactulose, oligomeric isomaltose, oligomeric isomaltulose, oligomeric glucose, Raffinose, stachyose, the chitosan, its use level is dose of 0.5g-30g/, the material of described extracted form natural plant comprises one or more in Citrus pericarp extract, Radix Ginseng extract, Folium Camelliae sinensis extract, Fructus Lycii extract, the Fructus Schisandrae Chinensis extrat, and its use level is dose of 0.5g-30g/.
4, according to claim 1 or 3 described Junyikang preparations, it is characterized in that: this Junyikang preparation also adopts one or more other intestinal beneficial bacterium fermentation back formulated, and described one or more bacillus bifidus and described one or more other intestinal beneficial bacterium can ferment respectively, also can mixed culture fermentation.
5, Junyikang preparation according to claim 4, it is characterized in that: described intestinal beneficial bacterium includes clostridium butyricum, bacillus acidophilus and streptococcus thermophilus, its use level is 1,000 ten thousand-400,000,000/one time doses of viable count.
6, Junyikang preparation according to claim 1, it is characterized in that: said preparation can be used as food, health product, medicine or food additive.
7, Junyikang preparation according to claim 1 is characterized in that: described Junyikang preparation can be made into capsule, microcapsule, electuary, granule, tablet, oral liquid.
8, Junyikang preparation according to claim 1 or 5 is characterized in that: also be combined with various vitamin and trace element in described Junyikang preparation.
9, manufacture a kind of production technology of the described Junyikang preparation of claim 1, it is characterized in that this Junyikang preparation makes through following method:
(1) prepares fermentation medium with distilled water, this fermentation medium contains one or more in tryptone, yeast extract, the beef extract, and oligofructose, glucose, the consisting of of this fermentation medium (its content is percetage by weight): tryptone 0.5%-4%, yeast extract 0.5%-4%, beef extract 0.5%-4%, oligofructose 0.5%-4%, glucose 0.5%-4%
(2) with culture medium under 121 ℃ of conditions, sterilized 30 minutes, when being cooled to 37 ℃, inoculate one or more bacillus bifidus, under 37 ℃ of conditions, cultivated 18 hours, the control bacteria containing amount reaches 2.2 * 10
9It is individual/as during ml, to reclaim with continuous centrifuge and to obtain wet thallus,
(3) above-mentioned wet thallus is suspended from PH is 5.6, concentration is in 20% the defatted milk powder liquid, abundant mixing, freeze-dried mycopowder, it is 4.0 * 10 that control contains viable count
10It is individual/g,
(4) above-mentioned lyophilizing mycopowder and one or more bifidus factors are by following use level mixed preparing, its use level is: the viable count of one or more bacillus bifidus is 1,000 ten thousand-400,000,000/one time doses, one or more bifidus factor is dose of 0.5g-30g/, makes the Junyikang preparation at last.
10, manufacture the described Junyikang preparation of claim 4, it is characterized in that this Junyikang preparation makes through following method:
(1) prepares fermentation medium with distilled water, this fermentation medium contains one or more in tryptone, yeast extract, the beef extract, and oligofructose, glucose, the consisting of of this fermentation medium (its content is percetage by weight): tryptone 0.5%-4%, yeast extract 0.5%-4%, beef extract 0.5%-4%, oligofructose 0.5%-4%, glucose 0.5%-4%
(2) with culture medium under 121 ℃ of conditions, sterilized 30 minutes, when being cooled to 37 ℃, inoculate one or more bacillus bifidus, with one or more intestinal beneficial bacterium, under 37 ℃ of conditions, to cultivate 18 hours, the control bacteria containing amount: the bacillus bifidus intestinal beneficial bacterium is respectively 2.2 * 10
9It is individual/as during ml, to reclaim with continuous centrifuge and to obtain wet thallus,
(3) above-mentioned wet thallus is suspended from PH is 5.6, concentration is in 20% the defatted milk powder liquid, abundant mixing, freeze-dried mycopowder, it is 4.0 * 10 that control contains viable count
10It is individual/g,
(4) above-mentioned lyophilizing mycopowder and one or more bifidus factors are by following use level mixed preparing, its use level is: the viable count of one or more bacillus bifidus is 1,000 ten thousand-400,000,000/one time doses, one or more intestinal beneficial bacterium is 1,000 ten thousand-400,000,000/doses, one or more bifidus factor is dose of 0.5g-30g/, makes the Junyikang preparation at last.
11, manufacture the described Junyikang preparation of claim 4, it is characterized in that this Junyikang preparation makes through following method:
(1) prepares fermentation medium with distilled water, this fermentation medium contains one or more in tryptone, yeast extract, the beef extract, and oligofructose, glucose, the consisting of of this fermentation medium (its content is percetage by weight): tryptone 0.5%-4%, yeast extract 0.5%-4%, beef extract 0.5%-4%, oligofructose 0.5%-4%, glucose 0.5%-4%
(2) with culture medium under 121 ℃ of conditions, sterilized 30 minutes, when being cooled to 37 ℃, inoculate one or more bacillus bifidus, under 37 ℃ of conditions, cultivated 18 hours, it is to reach 2.2 * 10 that control contains bacterium
9It is individual/as during ml, to reclaim with continuous centrifuge and to obtain wet thallus,
(3) above-mentioned wet thallus is suspended from PH is 5.6, concentration is in 20% the defatted milk powder liquid, abundant mixing, freeze-dried mycopowder, it is 4.0 * 10 that control contains viable count
10It is individual/g,
(4) with one or more intestinal beneficial bacterium seed liquor inoculation PH be 4.5, concentration is in 10% the defatted milk powder liquid, to cultivate 14 hours under 37 ℃ of conditions, obtains the intestinal beneficial bacterium fermentation liquid, it is 2.2 * 10 that control contains viable count
9Individual/ml.
(5) wet thallus of intestinal beneficial bacterium fermentation liquid and bacillus bifidus is suspended from PH is 5.6, concentration is in 20% the defatted milk powder liquid, abundant mixing, freeze-dried lyophilizing mycopowder, it is 4.5 * 10 that control contains viable count
10It is individual/g,
(6) above-mentioned lyophilizing mycopowder and one or more bifidus factors are by following use level mixed preparing, its use level is that the viable count of bacillus bifidus and intestinal beneficial bacterium is respectively 1,000 ten thousand-400,000,000/one time doses, bifidus factor is dose of 0.5g-30g/, makes the Junyikang preparation at last.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN97115093A CN1099289C (en) | 1997-08-01 | 1997-08-01 | Medicinal prepn. contg. beneficial bacteria named 'Junyikang' and method for preparing same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN97115093A CN1099289C (en) | 1997-08-01 | 1997-08-01 | Medicinal prepn. contg. beneficial bacteria named 'Junyikang' and method for preparing same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1192360A true CN1192360A (en) | 1998-09-09 |
| CN1099289C CN1099289C (en) | 2003-01-22 |
Family
ID=5173112
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN97115093A Expired - Lifetime CN1099289C (en) | 1997-08-01 | 1997-08-01 | Medicinal prepn. contg. beneficial bacteria named 'Junyikang' and method for preparing same |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1099289C (en) |
Cited By (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001085186A1 (en) * | 2000-04-26 | 2001-11-15 | Bingxin Wu | Preparation that contains the intestinal beneficial bacterium fermentation culture |
| CN1870910B (en) * | 2003-10-24 | 2010-05-26 | 努特里奇亚有限公司 | Synbiotic composition for infants |
| CN101314763B (en) * | 2007-06-01 | 2011-06-08 | 统一企业(中国)投资有限公司 | Short bifidobacteria with functions of anti-gastrointestinal tract pathogen, oxidation resistance and blood pressure reduction and its uses |
| CN102090558A (en) * | 2010-12-09 | 2011-06-15 | 上海交大昂立股份有限公司 | Composition containing probiotics, DHA (docosahexaenoic acid) and lactoferrin and applications thereof |
| CN101449830B (en) * | 2008-12-29 | 2012-01-11 | 山东龙力生物科技股份有限公司 | Mid-aged milk powder added with biostime and preparation method thereof |
| CN101711582B (en) * | 2009-08-28 | 2012-08-22 | 上海交大昂立股份有限公司 | Composition containing American ginseng extract and probiotics and application thereof |
| CN101336938B (en) * | 2007-07-02 | 2012-08-29 | 青岛东海药业有限公司 | Use of probiotics in preparing composition for treating and preventing hand-foot-mouth disease |
| CN102727530A (en) * | 2012-04-30 | 2012-10-17 | 威海康博尔生物药业有限公司 | Combination and application of probiotics and related prebiotics |
| CN102952771A (en) * | 2012-11-19 | 2013-03-06 | 陕西科技大学 | Streptococcus thermophilus freeze-drying protective agent and preparation method thereof |
| CN102960599A (en) * | 2012-11-19 | 2013-03-13 | 陕西科技大学 | Method for preparing bifidobacterium microcapsules containing prebiotics |
| CN103653170A (en) * | 2013-11-21 | 2014-03-26 | 荣成百合生物技术有限公司 | Stachyose probiotics solid beverage |
| CN104107194A (en) * | 2014-04-09 | 2014-10-22 | 南昌大学 | Making method of human intestinal micro-ecological system |
| CN104415061A (en) * | 2013-08-30 | 2015-03-18 | 深圳华大基因科技有限公司 | Edible composition as well as preparation method and application thereof |
| CN104489462A (en) * | 2014-12-09 | 2015-04-08 | 山东龙力生物科技股份有限公司 | Xylooligosaccharide probiotic powder |
| CN104489646A (en) * | 2014-11-19 | 2015-04-08 | 李雅君 | Fruit and vegetable probiotic tablet and preparation method thereof |
| CN104814442A (en) * | 2005-10-21 | 2015-08-05 | 努特里希亚公司 | Method for stimulating the intestinal flora |
| CN104957617A (en) * | 2015-06-30 | 2015-10-07 | 钟训艳 | Stachys probiotic composition |
| CN107022501A (en) * | 2016-05-03 | 2017-08-08 | 深圳市儿童医院 | Application of the bifidobacterium infantis in food hypersenstivity food or medicine is prevented and treated |
| CN107095885A (en) * | 2017-04-28 | 2017-08-29 | 青岛东海药业有限公司 | Application of the clostridium butyricum in prevention or treatment COPD preparation is prepared |
| CN108669563A (en) * | 2018-03-30 | 2018-10-19 | 北京斯利安药业有限公司 | A kind of composition, its application and strengthen immunity, the product for improving allergy |
| CN111956676A (en) * | 2020-08-24 | 2020-11-20 | 天津现代创新中药科技有限公司 | A microecological preparation containing Ginseng radix extract and probiotic bacteria, and its preparation method and application |
| CN113005066A (en) * | 2021-03-31 | 2021-06-22 | 盐城维康生物科技有限公司 | Compound bifidobacterium preparation with antiallergic, immunity enhancing, blood sugar reducing, blood fat reducing and weight losing functions and preparation method thereof |
| CN113424965A (en) * | 2021-06-29 | 2021-09-24 | 镇江远森医药科技有限公司 | Microecological preparation more suitable for yellow population |
| CN114437996A (en) * | 2022-03-25 | 2022-05-06 | 广西医科大学第一附属医院 | Heat-inactivated clostridium butyricum for preventing or treating asthma and preparation method thereof |
| CN114916676A (en) * | 2022-06-21 | 2022-08-19 | 河南省商业科学研究所有限责任公司 | Microencapsulated probiotic containing stachyose and konjac micropowder and preparation method thereof |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108741088A (en) * | 2018-05-29 | 2018-11-06 | 广州富诺营养科技有限公司 | Heat-resisting probiotic composition and health food comprising the composition |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1056750C (en) * | 1993-12-10 | 2000-09-27 | 济南三株药业有限公司 | Sanzhu oral liquid and its preparing method |
| CN1114354A (en) * | 1994-06-23 | 1996-01-03 | 江苏省纺织(集团)总公司实业开发分公司 | Aerobic fermentation process for Bifidobacterium in Chinese-medicinal culture medium |
| CN1112012A (en) * | 1995-03-08 | 1995-11-22 | 河北神力医药保健品厂 | Biological oral liquid |
| CN1055395C (en) * | 1995-04-05 | 2000-08-16 | 王世荣 | Ecological liubao oral liquid |
-
1997
- 1997-08-01 CN CN97115093A patent/CN1099289C/en not_active Expired - Lifetime
Cited By (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001085186A1 (en) * | 2000-04-26 | 2001-11-15 | Bingxin Wu | Preparation that contains the intestinal beneficial bacterium fermentation culture |
| CN1870910B (en) * | 2003-10-24 | 2010-05-26 | 努特里奇亚有限公司 | Synbiotic composition for infants |
| CN103230005B (en) * | 2005-10-21 | 2016-03-16 | 努特里希亚公司 | The method for the treatment of and/or preventing infections in infants delivered via caesarean section |
| CN104814442A (en) * | 2005-10-21 | 2015-08-05 | 努特里希亚公司 | Method for stimulating the intestinal flora |
| CN105124565A (en) * | 2005-10-21 | 2015-12-09 | 努特里希亚公司 | Method for stimulating the intestinal flora |
| CN101314763B (en) * | 2007-06-01 | 2011-06-08 | 统一企业(中国)投资有限公司 | Short bifidobacteria with functions of anti-gastrointestinal tract pathogen, oxidation resistance and blood pressure reduction and its uses |
| CN101336938B (en) * | 2007-07-02 | 2012-08-29 | 青岛东海药业有限公司 | Use of probiotics in preparing composition for treating and preventing hand-foot-mouth disease |
| CN101449830B (en) * | 2008-12-29 | 2012-01-11 | 山东龙力生物科技股份有限公司 | Mid-aged milk powder added with biostime and preparation method thereof |
| CN101711582B (en) * | 2009-08-28 | 2012-08-22 | 上海交大昂立股份有限公司 | Composition containing American ginseng extract and probiotics and application thereof |
| CN102090558A (en) * | 2010-12-09 | 2011-06-15 | 上海交大昂立股份有限公司 | Composition containing probiotics, DHA (docosahexaenoic acid) and lactoferrin and applications thereof |
| CN102727530A (en) * | 2012-04-30 | 2012-10-17 | 威海康博尔生物药业有限公司 | Combination and application of probiotics and related prebiotics |
| CN102952771A (en) * | 2012-11-19 | 2013-03-06 | 陕西科技大学 | Streptococcus thermophilus freeze-drying protective agent and preparation method thereof |
| CN102960599A (en) * | 2012-11-19 | 2013-03-13 | 陕西科技大学 | Method for preparing bifidobacterium microcapsules containing prebiotics |
| CN102952771B (en) * | 2012-11-19 | 2013-12-25 | 陕西科技大学 | Streptococcus thermophilus freeze-drying protective agent and preparation method thereof |
| CN104415061B (en) * | 2013-08-30 | 2016-06-01 | 深圳华大基因科技有限公司 | Edible composition and its production and use |
| CN104415061A (en) * | 2013-08-30 | 2015-03-18 | 深圳华大基因科技有限公司 | Edible composition as well as preparation method and application thereof |
| CN103653170B (en) * | 2013-11-21 | 2015-06-10 | 威海百合生物技术股份有限公司 | Stachyose probiotics solid beverage |
| CN103653170A (en) * | 2013-11-21 | 2014-03-26 | 荣成百合生物技术有限公司 | Stachyose probiotics solid beverage |
| CN104107194A (en) * | 2014-04-09 | 2014-10-22 | 南昌大学 | Making method of human intestinal micro-ecological system |
| CN104489646A (en) * | 2014-11-19 | 2015-04-08 | 李雅君 | Fruit and vegetable probiotic tablet and preparation method thereof |
| CN104489646B (en) * | 2014-11-19 | 2016-08-31 | 李雅君 | A kind of fruit and vegerable probiotic tablet and preparation method thereof |
| CN104489462B (en) * | 2014-12-09 | 2017-12-29 | 山东龙力生物科技股份有限公司 | A kind of xylo-oligosaccharide probiotic powder |
| CN104489462A (en) * | 2014-12-09 | 2015-04-08 | 山东龙力生物科技股份有限公司 | Xylooligosaccharide probiotic powder |
| CN104957617A (en) * | 2015-06-30 | 2015-10-07 | 钟训艳 | Stachys probiotic composition |
| CN107022501A (en) * | 2016-05-03 | 2017-08-08 | 深圳市儿童医院 | Application of the bifidobacterium infantis in food hypersenstivity food or medicine is prevented and treated |
| CN107095885A (en) * | 2017-04-28 | 2017-08-29 | 青岛东海药业有限公司 | Application of the clostridium butyricum in prevention or treatment COPD preparation is prepared |
| CN108669563A (en) * | 2018-03-30 | 2018-10-19 | 北京斯利安药业有限公司 | A kind of composition, its application and strengthen immunity, the product for improving allergy |
| CN111956676A (en) * | 2020-08-24 | 2020-11-20 | 天津现代创新中药科技有限公司 | A microecological preparation containing Ginseng radix extract and probiotic bacteria, and its preparation method and application |
| CN113005066A (en) * | 2021-03-31 | 2021-06-22 | 盐城维康生物科技有限公司 | Compound bifidobacterium preparation with antiallergic, immunity enhancing, blood sugar reducing, blood fat reducing and weight losing functions and preparation method thereof |
| CN113005066B (en) * | 2021-03-31 | 2023-07-21 | 江苏蓝泽生物科技有限公司 | Compound bifidobacterium preparation for resisting allergy, increasing immunity, reducing blood sugar and fat and losing weight and preparation method thereof |
| CN113424965A (en) * | 2021-06-29 | 2021-09-24 | 镇江远森医药科技有限公司 | Microecological preparation more suitable for yellow population |
| CN114437996A (en) * | 2022-03-25 | 2022-05-06 | 广西医科大学第一附属医院 | Heat-inactivated clostridium butyricum for preventing or treating asthma and preparation method thereof |
| CN114437996B (en) * | 2022-03-25 | 2024-03-15 | 广西医科大学第一附属医院 | Heat-inactivated clostridium butyricum for preventing or treating asthma and preparation method thereof |
| CN114916676A (en) * | 2022-06-21 | 2022-08-19 | 河南省商业科学研究所有限责任公司 | Microencapsulated probiotic containing stachyose and konjac micropowder and preparation method thereof |
| CN114916676B (en) * | 2022-06-21 | 2024-05-28 | 河南省商业科学研究所有限责任公司 | Microencapsulated probiotics containing stachyose and konjak micropowder and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1099289C (en) | 2003-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1099289C (en) | Medicinal prepn. contg. beneficial bacteria named 'Junyikang' and method for preparing same | |
| CN1663573B (en) | A stable and safe microecological formulation, its preparation and usage | |
| CN107893044B (en) | One plant of bifidobacterium longum and its application | |
| CN104542977B (en) | A kind of health beverages and preparation method containing yam extract and bifidobacterium bifidum | |
| CN1119154C (en) | Live triple bifidobacteria preparation and preparing method thereof | |
| CN106420847B (en) | Composition for assisting in protecting gastric mucosa and/or relieving gastrectasia and microecological preparation thereof | |
| CN102318806B (en) | Preparation method of probiotics fermented pumpkin and carrot vegetable powder | |
| CN1843385A (en) | Enteral microecological formulation and its preparation process | |
| CN103053904A (en) | Compound functional sugar with function of adjusting intestinal flora | |
| JP5000066B2 (en) | Conversion and modification of natural drugs by co-fermentative culture of intestinal symbiotic organisms | |
| CN105641209A (en) | Probiotics composition with function of improving immunity and preparing method and application of probiotics composition | |
| CN101744239A (en) | Application of dietary fibers in the preparation of pharmaceutical preparations for preventing and curing excrement smelling or excrement smelling poisoning syndrome | |
| CN101560523B (en) | Nutrient composition based on mixed fermented culture of five probiotics | |
| CN1480528A (en) | Bifidobacterium and products contg same | |
| CN105018408B (en) | It is a kind of to add the method that rutin promotes growth of probiotics in the medium | |
| CN1273838A (en) | Nutritive composition containing symbiotic fermentation culture medium of dead probiotics | |
| CN107397042A (en) | A kind of composite type animal enteron aisle regulation preparation and preparation method thereof | |
| CN109315769A (en) | It is a kind of for improving the composition and preparation method thereof of human body enteral environment | |
| CN113142302B (en) | Probiotic yogurt with blood glucose reducing effect and preparation method thereof | |
| CN110115292A (en) | Probiotics milk tablet for preventing dental caries and preparation method thereof | |
| CN110521785A (en) | Probiotics fermention functional food and its preparation | |
| CN109528814B (en) | Microecological preparation of lactobacillus fermented astragalus membranaceus as well as preparation method and application of microecological preparation | |
| CN106417989A (en) | Probiotic composition for aquatic animal feed, preparation method and application thereof | |
| CN108785331A (en) | It is a kind of that there is qi-blood tonifying composition and its preparation method and application | |
| CN101406489A (en) | Micro-ecological complex bacterial agent and method of preparing micro-ecological complex bacterial agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1037052 Country of ref document: HK |
|
| EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Qingdao Eastsea Pharmaceutical Co., Ltd. Assignor: Dongfanghaixin Biological Technology Co., Ltdd., Beijing Contract fulfillment period: 2007.8.30 to 2017.8.1 contract change Contract record no.: 2008370000095 Denomination of invention: Medicinal prepn. contg. beneficial bacteria named 'Junyikang' and method for preparing same Granted publication date: 20030122 License type: Exclusive license Record date: 2008.11.6 |
|
| LIC | Patent licence contract for exploitation submitted for record |
Free format text: EXCLUSIVE LICENSE; TIME LIMIT OF IMPLEMENTING CONTACT: 2007.8.30 TO 2017.8.1; CHANGE OF CONTRACT Name of requester: QINGDAO DONGHAI PHARMACY CO., LTD. Effective date: 20081106 |
|
| ASS | Succession or assignment of patent right |
Owner name: BEIJING POURKANG MEDICINE HIGH SCIENCE AND TECHNOL Free format text: FORMER OWNER: BEIJING DONGFANGBAIXIN BIOISYSTECH CO., LTD. Effective date: 20091106 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20091106 Address after: Beijing City, Haidian District Fuchengmen Road, Bai duizi (No. 131 Fucheng Road middle school building 5, room 101) Patentee after: Beijing Puerkang Medical High Technology Co., Ltd. Address before: Beijing City, Haidian District Bai duizi Fuchengmen Road No. 131 Patentee before: Dongfanghaixin Biological Technology Co., Ltdd., Beijing |
|
| CX01 | Expiry of patent term |
Granted publication date: 20030122 |
|
| CX01 | Expiry of patent term |